Based on the cash flow, Recce is running on fumes.
Basically relying on R&D advances for funds.
Unless the company:
• raises more cash
• is bought out
• enters into some form of arrangement with a large pharma
the end is near.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
-0.015(3.03%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 49.5¢ | 47.5¢ | $15.25K | 31.50K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11872 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 2600 | 2 |
View Market Depth
| Last trade - 15.40pm 02/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |